Paraoxonase Activity and Expression Is Modulated by Therapeutics in Experimental Rat Nonalcoholic Fatty Liver DiseaseReport as inadecuate




Paraoxonase Activity and Expression Is Modulated by Therapeutics in Experimental Rat Nonalcoholic Fatty Liver Disease - Download this document for free, or read online. Document in PDF available to download.

International Journal of HepatologyVolume 2012 2012, Article ID 265305, 9 pages

Research Article

Internal Medicine Department A, Ziv Medical Center, Safed 13100, Israel

Faculty of Medicine, Bar-Ilan University, 13100 Safed, Israel

Oncology Unit, Ziv Medical Center, Safed 13100, Israel

Pathology Department, Ziv Medical Center, Safed 13100, Israel

Biotechnology Department, Ort Braude College of Engeneering, Karmiel 21982, Israel

The Lipid Research Laboratory, Technion Faculty of Medicine, The Rappaport Family Institute for Research in the Medical Sciences and Rambam Medical Center, Haifa 31096, Israel

Received 11 November 2011; Revised 16 January 2012; Accepted 23 January 2012

Academic Editor: Manuela Neuman

Copyright © 2012 O. Hussein et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objective. The objective of the present study is to investigate the effect of rosiglitazone, metformin, ezetimibe, and valsartan alone or in combinations on paraoxonase PON activity and PON-mRNA expression in nonalcoholic fatty liver disease NAFLD. Methods. 54 Male Sprague–Dawley rats were divided to 9 groups: chow diet group 15 weeks; methionine-choline-deficient diet MCDD group 15 weeks; MCDD-treated groups for the last 6 weeks with either metformin M, rosiglitazone R, metformin plus rosiglitazone M+R, ezetimibe E, valsartan V, or a combination of R+M+V or of R+M+V+E for a total period of 15 weeks. Results. PON activities in serum and liver were decreased in MCDD rats. PON activity in serum increased significantly in all treatment groups. PON activity in liver was also increased significantly, except only in groups R, E, V, R+M+V, and R+M+V+E. Liver PON3 mRNA expression increased significantly in groups R+M, E, V, R+M+V, and R+M+V+E whereas liver PON2 mRNA expression increased significantly in MCDD, R+M, E, V, R+M+V, and R+M+V+E. Conclusions. PON activities in serum and liver were decreased in NAFLD. Treatment with insulin sensitizers, ezetimibe, and valsartan increased PON activity and reduced oxidative stress both in serum and liver.





Author: O. Hussein, J. Zidan, K. Abu Jabal, I. Shams, S. Szvalb, M. Grozovski, I. Bersudsky, R. Karry, and M. Aviram

Source: https://www.hindawi.com/



DOWNLOAD PDF




Related documents